Azithromycin Use in Atrial Fibrillation With Rapid Ventricular Response
Azithromycin is not contraindicated solely due to atrial fibrillation with rapid ventricular response. [1] Risk mitigation is required because azithromycin can cause QT interval prolongation and torsades de pointes in susceptible patients. [1]
QT Prolongation Risk Determinants in Azithromycin Labeling
Azithromycin labeling indicates that risk of QT prolongation (and torsades de pointes) should be considered in at-risk groups, including the following:
- Known QT interval prolongation. [1]
- History of torsades de pointes. [1]
- Congenital long QT syndrome. [1]
- Bradyarrhythmias or uncompensated heart failure. [1]
- Use of drugs known to prolong the QT interval. [1]
- Electrolyte abnormalities such as uncorrected hypokalemia or hypomagnesemia. [1]
- Concomitant use of Class IA antiarrhythmics (quinidine, procainamide) or Class III antiarrhythmics (dofetilide, amiodarone, sotalol). [1]
Atrial Fibrillation With RVR-Specific Interpretation
Atrial fibrillation with rapid ventricular response is not listed as a contraindication to azithromycin in labeling. [1] Tachycardia from RVR is not the labeled “at-risk” feature associated with torsades prevention measures. [1] The clinically relevant risk features are baseline QTc, electrolyte status, bradyarrhythmia status, and coadministration of additional QT-prolonging medications. [1]
Important Concomitant Medication Considerations
Coadministration with Class III antiarrhythmics is specifically identified as a higher-risk scenario for QT prolongation with azithromycin. [1] Coadministration with other QT-prolonging drugs is also identified as a higher-risk scenario. [1]
Clinical Monitoring and Risk-Reduction Approach
Baseline assessment for QT prolongation risk should include evaluation for known QT prolongation and correction of hypokalemia or hypomagnesemia. [1] Clinical vigilance is indicated for symptoms consistent with potentially serious arrhythmia (palpitations, dizziness, syncope) during therapy. [1]
Bottom-Line Clinical Determination
Azithromycin is generally not contraindicated due to atrial fibrillation with rapid ventricular response alone. [1] Azithromycin should be avoided or used with heightened caution when the patient has QT prolongation risk factors listed in azithromycin labeling, particularly known prolonged QTc, history of torsades, bradyarrhythmias, uncorrected hypokalemia or hypomagnesemia, or concomitant QT-prolonging antiarrhythmic therapy. [1]